At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 138 enrolled
Drug / intervention
BRN01 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Placebo-controlled Evaluation of the Homeopathic Drug BRN01 for the Treatment of Hot Flashes in Women With Non Metastatic Breast Cancer Treated by Adjuvant Hormonal Therapy
In Brief
A Phase 3 clinical trial evaluating BRN01 and Placebo for Breast Cancer. Completed, enrolled 138 participants across 9 sites.
Detailed Summary
The purpose of this study is to evaluate the efficacy of a homeopathic treatment (BRN01) in reducing hot flash scores after 4 weeks of treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesFrance
CollaboratorsBOIRON
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2010
First PostedNov 2010
Primary CompletionMay 2014
Study CompletionNov 2014
TodayJul 2026
First PostedNov 23, 2010
Enrollment StartJan 1, 2010
Primary CompletionMay 1, 2014
Study CompletionNov 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 15.6 years ago
Interventions
BRN01drug
2 tablets every morning and every evening during 8 to 10 weeks. Each patient will receive 1 set of 5 treatment boxes (60 tablets/box).
Placebodrug
2 tablets every morning and every evening during 8 to 10 weeks. Each patient will receive 1 set of 5 treatment boxes (60 tablets/box).